Skip to main content
ORIENTBIO Inc. logo

ORIENTBIO Inc. — Investor Relations & Filings

Ticker · 002630 ISIN · KR7002630002 KO Professional, scientific and technical activities
Open in API
Filings indexed 165 across all filing types
Latest filing 2025-06-13 Audit Report / Informat…
Country KR South Korea
Listing KO 002630

About ORIENTBIO Inc.

https://www.orientbio.co.kr

ORIENTBIO Inc. is a biotechnology company that supports drug discovery and biomedical research. The company's core activities involve the production and supply of laboratory animal models, such as mice and rats, for pharmaceutical companies, universities, and research institutions. In addition to providing research models, ORIENTBIO offers a range of biomedical contract services, including comprehensive health checks and genetic testing. The company also develops and distributes laboratory equipment and apparatus for experimental research.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2019.03)
Audit Report / Information Classification · 1% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Orient Bio, covering the fiscal period ending March 31, 2019. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes. Although it mentions a 'correction' (정정) and re-issuance in 2025, the core content is the audited financial statements themselves, not just an announcement of them. Therefore, it is classified as an Audit Report (AR). FY 2019
2025-06-13 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Orient Bio Co., Ltd. It includes the meeting date, location, agenda items (financial statements, board changes, etc.), and voting procedures (including electronic voting). It also contains detailed corporate governance information such as director activity reports and major shareholder transaction details, which are standard components of a proxy statement/notice of meeting in the Korean market. This document is the official solicitation and notification for the upcoming Annual General Meeting.
2025-06-12 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Orient Bio. It outlines the date, location, and agenda items (such as financial statement approval and board compensation). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-06-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 1% confidence The document is a regulatory filing from Orient Bio regarding a significant change in financial structure (30% or more change in revenue or profit/loss). It provides a summary table of financial data (revenue, operating profit, net income) and explains the reasons for the change. This is a standard periodic financial disclosure required by regulatory authorities (KRX) when financial results deviate significantly from previous periods. It is not a full annual report, but rather a specific financial disclosure announcement, which falls under the 'Regulatory Filings' category. FY 2024
2025-05-13 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for the upcoming 68th Annual General Meeting (AGM) to determine shareholder voting rights. It does not contain the full AGM materials or proxy statements, but rather serves as a formal notice of the record date. Given it is a regulatory announcement regarding meeting procedures that does not fit into specific report categories, it is classified as a general regulatory filing.
2025-03-14 Korean
분기보고서 (2024.12)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the 3rd quarter of the 68th fiscal year, submitted to the Financial Supervisory Service (FSS) and Korea Exchange. It contains detailed financial statements, management discussion and analysis, and business descriptions. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2024
2025-02-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.